Af­ter steer­ing through a con­tro­ver­sy over soar­ing price of nalox­one, FDA re­jects Am­phastar’s in­tranasal ver­sion

Af­ter com­ing un­der fire from an­gry law­mak­ers in the wake of its re­cent de­ci­sion to more than dou­ble the price of its opi­oid in­ter­ven­tion drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA